COR-1

DRUG2 trials

Sponsors

Corimmun GmbH

Conditions

Cardiomyopathy, DilatedHeart Failure

Phase 1

Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide

CompletedNCT01043146

Corimmun GmbHHeart Failure

Start: 2009-10-31End: 2010-01-31Updated: 2013-04-08

Phase 2

Pilot Study of COR-1 in Heart Failure

CompletedNCT01391507

Corimmun GmbHCardiomyopathy, Dilated

Start: 2011-10-31End: 2013-08-31Updated: 2014-10-17